April 12th 2024
Sarah Lee, MD, MBA, discussed a study to better disaggregate the subgroup of Asian American patients with ovarian cancer.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
In women with advanced epithelial ovarian cancer treated in a single-institution study at the Cleveland Clinic, the addition of paclitaxel to cisplatin for hyperthermic intraperitoneal chemotherapy during interval debulking surgery was associated with improved oncologic outcomes compared with cisplatin alone.
Read More
Specific HRD Testing Helps to Clarify the Role for PARP Inhibition in Ovarian Cancer
March 22nd 2021Eric Pujade-Lauraine, MD, PhD, discussed PARP inhibitors and the benefits of various testing methods for HRD, in an interview with Targeted Oncology ahead of the Society of Gynecologic Oncology Annual Meeting on Women's Cancer.
Read More
Apatinib/Doxorubicin Combination Improves PFS Over Single Agent in Ovarian Cancer
March 21st 2021The combination of apatinib and pegylated liposomal doxorubicin improved the progression-free survival for patients with platinum-resistant or refractory ovarian cancer in comparison to doxorubicin alone, according to data from the phase 2 APPROVE trial.
Read More
PFS Benefit Sustained at 5-Year Follow-Up in SOLO-1 Trial of Maintenance Olaparib in Ovarian Cancer
March 21st 2021After long-term follow-up, olaparib maintenance therapy demonstrated progression-free survival benefit in almost half of the patients with ovarian cancer compared with 21% for those who received placebo, including consistent benefit in high- and low-risk patients.
Read More
Niraparib Maintains PFS Improvement, But OS Data Are Limited in gBRCA+/- Ovarian Cancer
March 21st 2021Niraparib administered as maintenance therapy showed clinical benefit lasting beyond first progression in patients with platinum-sensitive recurrent ovarian cancer with or without germline BRCA mutations, according to the final results of the ENGOT-OV16/NOVA study.
Read More
Niraparib/Bevacizumab Combo Continues to Show Prolonged PFS in Patients With Advanced Ovarian Cancer
March 20th 2021At the Society of Gynecological Oncology Virtual Annual Meeting on Women’s Cancer data from the phase II OVARIO study continued to show the progression free survival benefit for heavily pretreated patients with advanced ovarian cancer.
Read More
CA-125 surveillance alone could be used to detect disease progression in patients with advanced ovarian cancer and an abnormal CA-125 level at the beginning of frontline maintenance therapy with olaparib (Lynparza) and bevacizumab (Avastin), according to an analysis from the phase 3 PAOLA-1 that was presented at the SGO 2021 Annual Meeting on Women’s Cancer.
Read More
PD-1/PARP Triplet Regimen Shows Positive Clinical Activity, Tolerability in Ovarian Cancer
March 20th 2021The addition of the investigational anti–PD-1 immunotherapy agent, dostarlimab, to niraparib and bevacizumab demonstrated positive antitumor activity and tolerability in patients with platinum-resistant ovarian cancer.
Read More
Rucaparib Improves PFS in BRCA+ Relapsed Ovarian Cancer in Confirmatory ARIEL4 Trial
March 20th 2021Compared with standard-of-care chemotherapy, treatment with the PARP inhibitor rucaparib led to a significant prolongation of progression-free survival and improved duration of response in patients with BRCA-mutated advanced, relapsed ovarian cancer, according to primary results from the phase 3 ARIEL4 trial.
Read More
Niraparib Shows Efficacy in Hard-to-Treat Patients With Newly Diagnosed Ovarian Cancer
March 19th 2021Data from a post hoc analysis of the PRIMA/ENGOT-OV26/GOG-3012 phase III trial showed the efficacy of niraparib maintenance therapy for patients with ovarian cancer who had interval debulking surgery or visible residual disease.
Read More
Historical and Current Data Inform the Ovarian Treatment Landscape for Practicing Oncologists
February 21st 2021Gynecologic oncology relies on both historical and modern therapies for the treatment of patients with ovarian cancer. During a Targeted Oncology Case-Based Peer Perspective virtual event, Michael J. Birrer, MD, PhD, reviewed the data.
Read More
Rucaparib Improves PFS in Patent With BRCA Mutation-Positive Relapsed Ovarian Cancer
December 21st 2020Treatment with rucaparib led to an improvement in investigator-assessed progression-free survival compared with chemotherapy in patients with relapsed ovarian cancer with a BRCA mutation who have received 2 or more prior lines of chemotherapy, meeting the primary end point of the phase 3 ARIEL4 clinical trial.
Read More
Olaparib Shows PFS Benefit at 5-Year Follow-Up in BRCA Ovarian Cancer
September 18th 2020Patients with newly diagnosed, advanced BRCA-mutated ovarian cancer who experienced complete or partial response following platinum-based chemotherapy continued to exhibit benefit in progression-free survival when receiving olaparib at long-term follow up versus placebo as first-line maintenance.
Read More